Immunosuppression-associated lymphoma in IBD

The Lancet

Volumn 374, Issue 9701, 2009, Pages 1572-1573

  D'Haens, Geert ^a,b   Rutgeerts, Paul ^a  

^a IMELDA HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CANCER RISK; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL LYMPHOMA; ULCERATIVE COLITIS;

CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; PATIENT SELECTION; PURINES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449127055     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61487-2     Document Type: Note

References (11)

1. Beaugerie L., Brousse N., Bouvier A.M., et al., for the CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 10.1016/S0140-6736(09)61302-7 published online Oct 19.
2. Travis S.P., Stange E.F., Lémann M., et al., for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 suppl 1 (2006) i16-i35
3. Caprilli R., Gassull M.A., Escher J.C., et al., for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55 suppl 1 (2006) i36-i58
4. Travis S.P., Stange E.F., Lémann M., et al., for the European Crohn's and colitis organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2 (2008) 24-62
5. Sandborn W., Sutherland L., Pearson D., et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2 (2000) CD000545.
6. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
7. Mackey C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
8. US Food and Drug Administration. Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) (Aug 4, 2009). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174 474.htm (accessed Aug 4, 2009).
9. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., and Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 7 (2009) 874-881
10. SEER. Non-Hodgkin lymphoma statistics. www.cdc.gov/cancer/hematologic/lymphoma/statistics (accessed Nov 6, 2007).
11. Sandborn W.J., Rutgeerts P.J., Reinisch W., et al. One year data from the Sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Gastroenterology 136 (2009) 751f